OR WAIT null SECS
May 06, 2016.
The Non-Small Cell Lung Cancer (NSCLC) market in Asia-Pacific (APAC) countries is set to experience strong growth from $2.7 billion in 2015 to $4.9 billion by 2022, according to GBI Research.
The company’s latest report states that immune-checkpoint inhibitors, such as Opdivo (recently awarded Pharm Exec's 2016 Brand of the Year) and Keytruda, will be particularly important drivers of growth, with Opdivo recently gaining approval in Japan, Australia and South Korea and the latter currently undergoing Phase III trials in Australia, Japan and South Korea.
NSCL drug sales will also be boosted in the Asia-Pac region by increasingly elderly populations, higher levels of pollution and passive smoking, and diversified market reform, GBI reports.
While a number of patents for important NSCLC drugs including Avastin (bavituximab), Alimta (pemetrexed), Tarceva (erlotinib) and Iressa (gefitinib), will all expire during the forecast period, the effect on the market is expected to be offset by the expected entry of targeted therapies.